Related references
Note: Only part of the references are listed.Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
Joshua D. Hansen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Rati Verma et al.
MOLECULAR CELL (2020)
A Facile Synthesis of Ligands for the von Hippel-Lindau E3 Ligase
Christian Steinebach et al.
SYNTHESIS-STUTTGART (2020)
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
Milka Kostic et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma
John M. Hatcher et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation
Jing Zhang et al.
CELL CHEMICAL BIOLOGY (2020)
p63 is a cereblon substrate involved in thalidomide teratogenicity
Tomoko Asatsuma-Okumura et al.
NATURE CHEMICAL BIOLOGY (2019)
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
Jiantao Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyI)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyppyrrolidine-2-carboxamide (VH298)
Pedro Soares et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Ian Churcher
JOURNAL OF MEDICINAL CHEMISTRY (2018)
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
James D. Phelan et al.
NATURE (2018)
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Mary E. Matyskiela et al.
NATURE CHEMICAL BIOLOGY (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
Crystal structure of human IRAK1
Li Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma
Anupama Reddy et al.
CELL (2017)
Small-Molecule Modulation of Protein Homeostasis
George M. Burslem et al.
CHEMICAL REVIEWS (2017)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of Halo Tag Fusion Proteins
Dennis L. Buckley et al.
ACS CHEMICAL BIOLOGY (2015)
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
Patrick R. Hagner et al.
BLOOD (2015)
Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications
Georg Lenz
CANCERS (2015)
Structure-Guided Design and Optimization of Small Molecules Targeting the Protein Protein Interaction between the von Hippel- Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
Carles Galdeano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Diffuse large B-cell lymphoma-treatment approaches in the molecular era
Mark Roschewski et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Molecular Mechanisms of System Control of NF-κB Signaling by IκBα
Diego U. Ferreiro et al.
BIOCHEMISTRY (2010)
Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling
Su-Chang Lin et al.
NATURE (2010)
IRAK-4 inhibitors. Part 1: A series of amides
George M. Buckley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Share Paper
